Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

160.13 +0.27 (+0.17%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?
Johnson & Johnson discontinues the Phase 3 SunRISe-2 trial for TAR-200 in bladder cancer, citing lack of superiority. Q3 earnings forecasted to hit $22.26 billion with 4.4% growth, as the company eyes... 
Via Benzinga
Exposures Product Safety
Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio
Risk-averse investors can build a stable portfolio by focusing on established companies with consistent dividends and proven track records of success. 
Via MarketBeat
3 Undervalued Dividend Stocks Primed for Growth in 2025
These quality dividend stocks look significantly undervalued which gives you an opportunity to pair a high-yield dividend with strong capital appreciation 
Via MarketBeat
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson's Options: A Look at What the Big Money is Thinking
Via Benzinga
In-Depth Analysis: Johnson &amp; Johnson Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data... 
Via Benzinga
2 Smart Income Stocks to Buy Right Now
These storied companies have a lot to offer different investors. 
Via The Motley Fool
3 Industries Set To Explode When Interest Rates Drop
Via Talk Markets
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
The Latest Analyst Ratings For Johnson & Johnson
Via Benzinga
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, while also announcing a $2 billion biologics facility to support its expanding... 
Via Benzinga
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by... 
Via Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
These 15 dividend stocks can deliver stable passive income for life. 
Via The Motley Fool
2 Excellent Dividend Stocks to Buy With Less Than $200
Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years. 
Via The Motley Fool
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
Via Investor's Business Daily
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other therapies, demonstrating significant potential in treating relapsed or refractory... 
Via Benzinga
For those who appreciate value investing, NYSE:JNJ is a compelling option with its solid fundamentals.
JOHNSON & JOHNSON (NYSE:JNJ) is an undervalued gem with solid fundamentals. 
Via Chartmill
Why Masimo Stock Crushed the Market Today
The company seems to be effecting a smooth transition in its leadership. 
Via The Motley Fool
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
These dividend players could lift your portfolio no matter what the market is doing. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Is Johnson & Johnson Stock a Buy?
This healthcare blue chip is making all the right moves to reward shareholders. 
Via The Motley Fool
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
From Beasley Allen Law Firm
Via Business Wire
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
From Johnson & Johnson
Via Business Wire
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
Johnson & Johnson's Rybrevant (amivantamab) received FDA approval for use with standard chemotherapy in advanced non-small cell lung cancer with specific EGFR mutations. 
Via Benzinga
Exposures Product Safety
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.